Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,194,299
  • Shares Outstanding, K 146,662
  • Annual Sales, $ 0 K
  • Annual Income, $ -422,770 K
  • EBIT $ -548 M
  • EBITDA $ -575 M
  • 60-Month Beta 1.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.59

Options Overview Details

View History
  • Implied Volatility 64.11% (+0.36%)
  • Historical Volatility 57.54%
  • IV Percentile 5%
  • IV Rank 9.56%
  • IV High 155.38% on 11/13/25
  • IV Low 54.46% on 08/18/25
  • Expected Move (DTE 16) 2.86 (13.75%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 221
  • Volume Avg (30-Day) 254
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 5,278
  • Open Int (30-Day) 3,588
  • Expected Range 17.91 to 23.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.75
  • Number of Estimates 12
  • High Estimate -0.62
  • Low Estimate -0.93
  • Prior Year -0.67
  • Growth Rate Est. (year over year) -11.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.34 +38.07%
on 01/05/26
23.77 -10.90%
on 02/03/26
+4.91 (+30.18%)
since 01/02/26
3-Month
13.75 +54.04%
on 11/07/25
23.77 -10.90%
on 02/03/26
+6.26 (+41.96%)
since 11/04/25
52-Week
10.57 +100.38%
on 04/07/25
24.34 -13.00%
on 02/05/25
-1.81 (-7.87%)
since 02/04/25

Most Recent Stories

More News
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicleâ„¢ Programs at the 2026 WORLDSymposiumâ„¢

SOUTH SAN FRANCISCO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that management will host a live webcast to review presentations on its Enzyme TransportVehicleâ„¢...

DNLI : 21.47 (-1.42%)
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicleâ„¢ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposiumâ„¢

Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority Review Preliminary data from Phase...

DNLI : 21.47 (-1.42%)
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome

Preparing for FDA approval and commercial launch of tividenofusp alfa, Denali’s TransportVehicle™ (TV)-enabled investigational therapy for Hunter syndrome Expecting multiple clinical data readouts...

DNLI : 21.47 (-1.42%)
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints including adaptive behavior, cognition and hearing, and normalization...

DNLI : 21.47 (-1.42%)
Beyond Weight Loss: The "Cellular Reset" That Could Create the Next Biotech Supercycle

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity economy is entering a massive repricing event as researchers confirm that metabolic dysfunction...

LGVN : 0.5398 (-2.30%)
AVAI : 0.4700 (-6.00%)
BIOA : 19.80 (-0.55%)
GAA : 34.12 (+0.83%)
DNLI : 21.47 (-1.42%)
MAPT : 0.0003 (unch)
KLTO : 0.2529 (-3.21%)
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common...

DNLI : 21.47 (-1.42%)
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $200 million of shares of its common stock and,...

DNLI : 21.47 (-1.42%)
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty...

RPRX : 43.62 (+1.51%)
DNLI : 21.47 (-1.42%)
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty...

RPRX : 43.62 (+1.51%)
DNLI : 21.47 (-1.42%)
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Tividenofusp alfa BLA review process for accelerated approval for MPS II continues with productive engagement with the FDA; commercial launch preparations on track DNL126 Phase 1/2 study enrollment completed,...

DNLI : 21.47 (-1.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program...

See More

Key Turning Points

3rd Resistance Point 25.71
2nd Resistance Point 24.74
1st Resistance Point 23.26
Last Price 21.47
1st Support Level 20.81
2nd Support Level 19.84
3rd Support Level 18.36

See More

52-Week High 24.34
Last Price 21.47
Fibonacci 61.8% 19.08
Fibonacci 50% 17.46
Fibonacci 38.2% 15.83
52-Week Low 10.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar